GlassScriptPhysician profile
David R Long
NPI 1114946480
$7,553.82
in general payments reported to CMS, 2019-2025
55 companies · $1,774 in 2025
The $1,774 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $245 · 2021: $1,218 · 2022: $957 · 2023: $1,324 · 2024: $1,374 · 2025: $1,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,472.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,467.11 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $710.98 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $430.67 | 2021-2025 | Trintellix |
| Pfizer INC. | $400.47 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $373.81 | 2022 | |
| Astellas Pharma US INC | $361.60 | 2023-2025 | Veozah |
| Novo Nordisk INC | $346.99 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $338.82 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $329.57 | 2021 | |
| Lilly USA, LLC | $317.37 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $228.39 | 2019-2024 | Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $167.20 | 2022-2025 | Seglentis, Livalo, Zoryve |
| Axsome Therapeutics, INC. | $160.07 | 2023-2025 | Auvelity, Symbravo |
| Celgene Corporation | $151.38 | 2019 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.